Five things for pharma marketers to know: Friday, November 11, 2016
1. President-elect Donald Trump released new information about his healthcare plan. He plans to replace the Affordable Care Act, reform the FDA, and modernize Medicare. The plan does not address drug costs. (Bloomberg)
2. Analysts say that Trump's presidency will likely mean an influx in pharmaceutical M&A activity. Life sciences companies have made far fewer deals this year than in the past, with dealmaking down 65% in August 2016 versus the year-ago period. (Reuters)
3. A superbug is causing life-threatening infections in people with cystic fibrosis and has become increasingly virulent, researchers said. The bacteria can cause severe pneumonia. (Reuters)
4. Private equity firm Advent International closed its deal with InVentiv Health. Advent and Thomas H. Lee Partners are now equity owners in inVentiv Health, which is valued at $3.8 billion.
5. ICYMI: Alexion Pharmaceuticals' board of directors is investigating allegations that the company engaged in improper sales practices for its drug Soliris, which is used to treat the blood disorder paroxysmal nocturnal hemoglobinuria and hemolytic uremic syndrome. A former employee made the allegations. (WSJ)